Details
Stalevo Indications
Parkinson's disease. Movement disorders (instability) caused inefficiency dosage in the treatment of levodopa / dopa-decarboxylase inhibitors.
Contraindications
Hypersensitivity to levodopa, carbidopa, entakaponu or to any component of the drug.
Severe hepatic insufficiency.
Pheochromocytoma.
Accompanying the drug steel with non-selective inhibitor of monoamine oxidase (MAO-A and MAO-B) (eg, phenelzine, tranyltsyprominom).
Additional admission selective inhibitors of MAO-A and MAO-B with steel.
Neuroleptic Malignant Syndrome (CNS) and / or nontraumatic rhabdomyolysis in history.
Undiagnosed skin disorders or a history of melanoma.
Severe heart failure. Severe cardiac arrhythmia.
Severe psychosis.
Dosage & Administration
The tablets should be taken orally, regardless of food intake.
One pill contains a therapeutic dose, so you need to take a pill.
The optimal daily dose of steel for each patient should be carefully selected. The daily dose steel optimized by applying one of the following concentrations steel: 50 / 12.5 / 200 mg, 100/25/200 mg, 150 / 37.5 / 200 mg, or 200/50/200 mg of levodopa / carbidopa / entakaponu.
Patients should be warned about receiving only one tablet of steel selected dose. Patients receiving less than 70-100 mg carbidopa a day, there may be nausea and vomiting. As the experience with total daily dose of more than 200 mg carbidopa is limited, and the maximum recommended daily dose of 2000 mg entakaponu, the maximum daily dose of 10 steel tablets dosages of 50 / 12.5 / 200 mg, 100/25/200 mg, 150 / 37.5 / 200 mg and 7 tablets dosage 200/50/200 mg.
Typically steel is used in patients who are currently taking the appropriate dose of levodopa or dopa-decarboxylase inhibitors with standard release and entakapon.
